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“Take home” message 
There are no focused international guidelines for the management of acute 
exacerbations of IPF (AE-IPF) resulting in global variability in prevention, diagnosis 
and treatment strategies. Global trials to evaluate these approaches are urgently 








Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an often deadly 
complication of IPF. No focused international guidelines for the management of AE-
IPF exist. The aim of this international survey was to assess the global variability in 
prevention, diagnostic and treatment strategies for AE-IPF. 
Material and methods 
Pulmonologists with ILD expertise were invited to participate in a survey designed by 
an international expert panel. 
Results 
509 pulmonologists from 66 countries responded. Significant geographical variability 
in approaches to manage AE-IPF was found. Common preventive measures 
included antifibrotic drugs and vaccination. Diagnostic differences were most 
pronounced regarding use of KL-6 and viral testing, while HRCT, BNP and D-Dimer 
are generally applied. High dose steroids are widely administered (94%); the use of 
other immunosuppressant and treatment strategies is highly variable. Very few (4%) 
responders never use immunosuppression. Antifibrotic treatments are initiated during 
AE-IPF by 67%. Invasive ventilation or extracorporeal membrane oxygenation are 
mainly used as a bridge to transplantation. Most physicians educate patients 
comprehensively on the severity of AE-IPF (82%) and consider palliative care (64%). 
Conclusion: 
Approaches to the prevention, diagnosis and treatment of AE-IPF vary worldwide. 













Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrosing interstitial 
lung disease with a 20-40% five-year survival rate and a median survival time of 2-5 
years.(1) Acute exacerbation of IPF (AE-IPF) is often the primary cause of death in 
patients with this disorder.(2)   
AE-IPF is defined as an acute, clinically significant respiratory deterioration 
characterised by evidence of new widespread alveolar abnormality. Diagnostic 
criteria are: previous or concurrent diagnosis of IPF, acute worsening or development 
of dyspnoea within 1 month duration, computed tomography with new bilateral 
ground-glass opacity and/or consolidation on a background pattern with usual 
interstitial pneumonia pattern and deterioration not fully explained by cardiac failure 
or fluid overload.(3) The incidence varies between 7 to 32%, and current evidence 
suggests that up to 46% of deaths in IPF are associated with AE-IPF.(6) In-hospital 
mortality after AE-IPF exceeds 50% (2, 4, 5), and the median survival after AE-IPF is 
approximately 3 to 4 months.(6) AE-IPF may be either triggered, e.g. by infection, 
post-procedural/postoperative, drug toxicity, aspiration or might be idiopathic.(6) 
Currently, no focused international guidelines exist regarding the prevention, 
diagnosis or therapy of AE-IPF.(3, 6) While the clinical practice guideline for IPF 
provides a weak recommendation for treatment with steroids, this recommendation is 
based on expert opinion and there is no specific guidance on dose, route, and 
duration or diagnostic or therapeutic approaches. Data from clinical trials especially 
on the treatment of AE-IPF are sparse and currently, there are no large randomized 
controlled trial data on AE-IPF available.  
We hypothesized that clinical approaches to the investigation and 
management of suspected AE-IPF might vary substantially, which may inform us 
about priority research questions to be addressed. Therefore, this study aimed to 
explore preventive, diagnostic and therapeutic strategies towards AE-IPF in an 
international group of respiratory physicians to guide future clinical trial design and 






Materials and methods 
Questionnaire and participating physicians 
To identify the items to be included in this survey, we conducted a literature research 
on diagnostics, therapy, prevention and management of AE-IPF on 
https://www.ncbi.nlm.nih.gov/pubmed, https://scholar.google.com and others 
(supplementary 1). Next, an expert panel was created, comprising respiratory 
physicians with expertise in the diagnosis and management of ILD working in 
specialist ILD centers and a track record of publication in this field, to participate in an 
email-based interview to structure the survey. The final questionnaire consisted of 20 
questions regarding diagnosis, treatment and prevention of AE-IPF and suggested 
future perspectives in AE-IPF research (supplementary 2). Additionally, optional 
questions were included on working place (including ILD-expert centers versus non-
expert centers), country of origin, number of patients with IPF under care, and 
estimated number of AE-IPF seen.  
 
An internet search was performed from July 1, 2017 to November 30, 2017 to 
identify practising respiratory physicians worldwide with interest in ILD. This search 
included the European Respiratory Society assembly on Diffuse Parenchymal Lung 
Disease, the American Thoracic Society assembly on Clinical Problems, the 
Japanese Respiratory Society assembly on Diffuse Parenchymal Lung Disease and 
participants of the IPF Project Consortium (www.theipfproject.com)(7). Nationality, 
academic status (working at a university hospital or not) or subspecialist interests 
within respiratory medicine did not influence inclusion eligibility. Pulmonologists were 
invited to participate via an e-mail link. The questionnaire was available on the online 
survey tool SurveyMonkey® from December 2017 to April 2018. 
 
Statistical analysis  
For questions with categorical answers, absolute and relative frequencies were 
calculated and differences between continents were assessed using chi-squared 
tests. For questions with answers on a continuous scale, median, first and third 
quartile, minimum and maximum were determined and differences between 
continents were assessed using Kruskal-Wallis tests. Due to the exploratory nature 
of this survey, all resulting p-values are solely to be interpreted descriptively and no 
adjustment for multiple testing was conducted. P-values smaller than 0.05 were 






Overall, 509 pulmonologists from 66 countries responded. 42.6 % (n=217) were from 
Europe, 26.7 % (n=136) from Asia, 11.2 % (n=57) from North America, 9.8 % (n=50) 
from South America, 4.9 % (n=25) from Australia (including New Zealand), 1 % (n=5) 
from Africa and 3.7 % (n=19) remained anonymous (figure 1a and figure 1b). 66% of 
the participants worked in a specialised ILD center/university hospital, 28% in general 
pulmonology departments/non-university centers and 1% on an intensive care unit 
(5.3% in others). The average number of IPF patients under care was 130; the 
estimated median number of patients with AE-IPF seen per year was 18. Overall, 1-
year mortality of patients with AE-IPF was estimated to 50-80% by 41.9%, 20-50% by 
35.1%, >80% by 14.7% and <20% by 8.4%.  
 
Diagnostic procedures for AE-IPF 
HRCT (multi-slice thin-section CT, without contrast media) was performed by 76% 
participants with the highest rates in Asia (91%) and lowest in Europe (67%). CT with 
contrast media was applied less frequently (34%) but even in the absence of a 
clinical suspicion of pulmonary embolism. Most physicians used it in Europe (45%), 
fewest in Asia (20%) and Africa (20%). 
Echocardiography to screen for cardiac reasons for deterioration was used by 66%. 
NT-proBNP/BNP (72%), D-Dimer (64%) and troponins (50%) were used widely 
during the diagnostic workup of an AE-IPF. As a biomarker for AE-IPF, KL-6 was 
used in Asia (54%), but not elsewhere.  
Bronchoalveolar lavage (BAL) in the context of AE-IPF was always performed 
by 5.8%, while the majority (70.5%) only performed BAL in case of suspected 
infection. For microbiology assessments, mainly sputum was collected (85%) while 
induced sputum was sampled by 14%. Specific pathogen screening for influenza 
viruses (75.7%), atypical bacterial pathogens (61.8%) and Pneumocystis jiroveci 
(58.6%) was common. Only a minority screened for other pathogens like RSV 
(44.4%), CMV (37.8%), Aspergillus (37.6%), Candida (17%) and tuberculosis 
(10.9%). A minority (9.2%) did not screen for any specific infections.  
The main diagnostic procedures applied for AE-IPF, which vary significantly between 
the continents, are shown in Figure 1 (further results can be seen in supplementary 
3, table 1). 
 
 
Treatment approaches for AE-IPF 
The majority of participating pulmonologists treated AE-IPF with methylprednisolone 
or equivalent with a dosage of 500-1000 mg per day for 3 days followed by a slow 
tapering (63%), while 11% applied pulsed high dose steroids for 3 days only. 31% 
used prednisolone with a dosage of 1 mg/kg per day followed by a slow tapering. On 
average, physicians treated AE-IPF with corticosteroids for 13 weeks.  
Other immunosuppressive therapies were rarely used: 19% use 
cyclophosphamide (i.v. bolus), 9% cyclosporine, 5% tacrolimus and 4% rituximab. 
Differences between continents in the use of immunomodulators were significant 
(table 2). For instance, cyclophosphamide was used by 28% in Asia and never in 
North America. Only a minority never treated AE-IPF with any immunosuppressive 
therapy (4%).  
Other therapies such as polymyxin B hemoperfusion, recombinant thrombomodulin 
and plasmapheresis/plasma exchange were used primarily in Asia (supplementary 3, 
table 2). 
Antimicrobial therapy was commenced regularly by 56% with broad-spectrum 
antibiotics combined with macrolides. 23% only used antibiotic treatment in case of a 
clinical and/or laboratory indication of a bacterial infection.  
In AE-IPF patients without previous antifibrotic therapy, most participants 
would have initiated such therapy (nintedanib: 21%, pirfenidone: 14%, either 
nintedanib or pirfenidone: 32%), while 33% did not see an indication for an antifibrotic 
treatment in the acute setting. Most physicians (71%) would have waited until clinical 
stabilisation before initiating antifibrotic therapy. In patients already on antifibrotic 
therapy at the time of AE-IPF, 76% of respondents recommended its continuation, 
while a minority would have advised differently (4%: discontinue, 3%: reduce dose, 
10%: switch the antifibrotic drug). For gastroesophageal reflux disease (GERD), 19% 
always initiated or increased antacid therapy during AE-IPF (supplementary 3, table 
2). The main management approaches are shown in figure 3. 
 
In case of respiratory failure, invasive ventilation was offered to all patients by 9%, 
and by 45% only to patients suitable for lung transplantation (LTX), as a bridge to 
LTX or in very selected other cases. Extracorporeal membrane oxygenation (ECMO) 
was offered to patients suitable for LTX as a bridge to LTX by 44%, mostly in Europe 
(57%) and fewest in Oceania (24%). Critically ill patients with AE-IPF were offered 
high-flow oxygen by 81% and non-invasive ventilation (NIV) by 74%. Palliative care 
was considered by 65%. Differences in these approaches were again significant 
between continents (supplementary 3, table 3). 
 
 
Preventive strategies for AE-IPF 
Measures aiming to prevent AE-IPF were mainly vaccinations (i.e. influenza, 
pneumococcal) (93%), antifibrotic therapy (86%) and pulmonary rehabilitation or 
other forms of structured exercise therapy (58%). Antacid drugs were prescribed by 
52% respondents in all IPF patients. Only a minority used long-term azithromycin 
(7%) or low dose steroids (≤10 mg) (4%). There were significant differences 
concerning prevention of AE-IPF between the continents (table 4). For instance, most 
physicians in Europe valued antifibrotic therapy as a preventive strategy (90%), 
opposed to significantly fewer in Asia (79%). Anticoagulation was only used by a 
minority (2%).  
In terms of planned surgical procedures, 69% favoured preventive anaesthetic 
measures such as low tidal volume and avoidance of hyperoxygenation as well as 
regional anaesthesia over general anaesthesia when possible. 15% avoided any 
elective thoracic surgery. Differences between continents were again significant 
(figure 4 and supplementary 3, table 4).  
 
Unmet needs in AE-IPF 
According to respondents, more research into treatment (86%), and improving our 
understanding of the pathophysiology of AE-IPF (83%) is needed. Furthermore, most 
respondents highlighted the need for consensus guideline recommendations for AE-
IPF (79%), improved education and training of physicians (66.5%) and patients and 
caregivers (60%). 60% see a need for improvement in the collaboration between 
different ILD specialists in general and 58% in multidisciplinary strategies for 





Despite AE-IPF being a primary driver of mortality in IPF (3), evidence on prevention, 
additional diagnostic approaches besides HRCT and especially on treatment of this 
complication is sparse and evidence-based guidance particularly is missing. Our 
results, which are drawn from a large international group of respiratory physicians 
with expertise in the management of IPF, reveal many similarities, e.g. the use of 
HRCT for the diagnosis or the use of steroids for the treatment. But there are also 
significant differences in the approach to AE-IPF such as in the therapy strategies 
beyond steroids.  
The majority of physicians use sputum analysis, HRCT, BNP, BAL in suspected 
infection and D-Dimer for the differential diagnosis of AE-IPF, while diagnostic 
approaches differ regarding the use of KL-6 and viral testing.  
As for treatment, high dose steroids are widely administered but the use of 
immunosuppressants and other strategies are highly variable. Very few respondents 
never use immunosuppression. There are also differences in the use of antifibrotic 
drugs in the context of AE-IPF. These results reflect an unmet need for clinical 
practice guidelines in this disorder.  
 
Regarding diagnostic procedures in AE-IPF, surprisingly less than 80% of 
participants use HRCT despite the current definition of AE-IPF requiring evidence of 
new parenchymal changes on HRCT.(3) Moreover, HRCT might be critical in 
determining the prognosis as the extent and distribution of HRCT patterns during AE-
IPF may predict outcome.(8) CT with contrast media is used by 34% of the 
participating physicians. Usually it is used in the process of excluding pulmonary 
embolism.(9) This is a very important tool because IPF patients are more likely to 
have a prothrombotic state compared to healthy individuals and this has an impact 
on survival.(10) 
Blood-based biomarkers in AE-IPF may also have prognostic value; KL-6 and serum 
decorin are reported to be predictive of AE-IPF in a Japanese population.(11, 12) 
Based on low level evidence there are data proving that the bacterial load and the 
bacterial spectrum in patients with AE-IPF differs significantly from a stable 
disease,(13) many clinicians search for pathogens, however significant differences in 
treatment practice of viral and bacterial infections exist. A recent retrospective 
analysis of azithromycin was associated with a reduced mortality in AE-IPF 
compared to fluoroquinolones (14) but it remains unclear if the reduced mortality is 
explained by a possible harmful effect of fluoroquinolones. Furthermore, it is unclear 
if azithromycin may be useful in all forms of AE-IPF or only in AE-IPF caused by 
infection. Ding et al. could show that the use of Procalcitonine may prevent an 
unnecessary use of antibiotics in AE-IPF.(15)  
Viruses are established triggers for acute respiratory failure in chronic diseases (16), 
however data on associations of viral infections in AE-IPF are contradictory.(17, 18) 
This may explain the rare use of antivirals such as aciclovir (1%) and ganciclovir 
(2%) in the treatment of AE-IPF. 
 
The need for a general worldwide approach to treatment is mirrored in the lack of 
general guidance except an expert weak recommendation for treatment with steroids 
in the current international guideline.(6) In particular, more evidence for the use of 
high dose steroids, commonly used in AE-IPF by the participants in this study, is 
required. While no data exist on outcomes associated with the use of steroids in AE-
IPF, high dose long-term steroid use was associated with an increased mortality in 
the PANTHER trial (19) and a history of previous immunosuppression before IPF-AE 
has a negative impact on mortality.(20) Notable, some physicians use an even more 
potent anti-inflammatory treatment approach, e.g. cyclosporine A, intravenous 
cyclophosphamide and tacrolimus (mainly in Asia, Rituximab mostly in North and 
South America), although there is low or very low evidence for the use of these 
treatments.(21-25) Therefore, further trials are needed.  
A majority of participants report prescription of antifibrotics as a way to prevent 
AE. Controlled trials suggest that nintedanib may prolong the time to the first AE-
IPF(26), while post-hoc data on pirfenidone suggest that it may reduce the risk for 
respiratory related hospitalisation.(5) There is no robust data whether antifibrotics 
ameliorate the course of AE-IPF in patients with acute respiratory failure. Current 
registries have to be analyzed to obtain more information on this topic and the 
survival during and after AE-IPF. ILD experts already aim to do so.(27)   
Some prospective randomized trials are currently ongoing, such as a French study 
assessing the role of cyclophosphamide on top of pulsed steroids (NCT02460588), 
two studies assessing the effect of therapeutic plasma exchange, rituximab and 
intravenous immunoglobulins for severe AE-IPF patients admitted to ICU 
(NCT03584802) and a study from Japan assessing the effect of recombinant 
thrombomodulin in addition to standard of care with steroid therapy (NCT02739165). 
These studies and others will hopefully address some of the key unresolved issues 
regarding treatment of AE-IPF. 
 
The definition of idiopathic AE-IPF relies on the exclusion of other aetiologies, 
including infection.(3) However, only a minority used bronchoscopy with BAL. A 
recent study does not support this approach as a positive bronchoscopy only affected 
management in 13% of patients and resulted in a change of treatment in less than 
5%. In the same study, bronchoscopy resulted in a significant number of patients 
transferred to the ICU intubated and similarly a significant number of patients could 
not be extubated after the procedure.(28) In contrast, another report demonstrated 
the feasibility and safety of BAL aided by NIV as a useful tool for differentiating or 
confirming triggered AE.(29) It has to be discussed whether collection of bronchial 
secretion via bronchoscopy might be better tolerable and at least equally effective in 
suspected infection in AE-IPF. Yet, this has to be evaluated in future trials.  
The mortality of patients with AE-IPF admitted to ICU, particularly in ventilated 
patients, is high.(30) Therefore, the international guidelines recommend avoiding ICU 
in patients with AE-IPF (weak recommendation).(31) NIV and high-flow oxygen are 
often initiated in critical ill patients but data on this is limited.(9, 32) Other advanced 
therapies such as invasive ventilation and ECMO are usually only used as a bridge to 
LTX. This is in line with the current literature (33, 34) and thus included in the 
recommendations of the international guidelines.(6)  
Vaccinations theoretically play an important role in the prevention of AE-IPF, but 
while their use is recommended by the international guideline there is a paucity of 
evidence to support this recommendation.(35) Also it is not clear how local public 
health systems are dealing with this vaccinations and to what extent these are 
available. Many physicians use anti-acid drugs as a preventive strategy for AE-IPF, 
although evidence on the role of anti-acids in IPF is controversial. Lee et al. reported 
a higher pepsin level in the BAL of patients with AE-IPF compared to patients with 
stable diseases (36) and also showed a positive impact of antacid drugs on the 
course of IPF in retrospective analyses.(37, 38) However, recent studies could not 
support this effect and reported potentially higher rates of respiratory infections (39) 
and AE-IPF(40).  Only a few physicians use low dose steroids as a preventive 
strategy for AE-IPF. This is in line with the international guideline that do not 
recommend the use of steroids beyond AE-IPF.(31) Amongst other data, this 
recommendation is based on the results of the PANTHER trial that demonstrated an 
increased risk of hospitalisation and death for patients receiving combination therapy 
with N-acetylcyteine, azathioprine and prendnisolone compared to controls.(19) 
Moreover, the use of corticosteroids does not have a positive effect on the outcome 
of IPF patients who receive nintedanib.(41) In the end there is no data proving a 
benefit for the indication for steroids in the prevention of AE-IPF.  
Even though IPF patients are more likely to have a prothrombotic state (as 
mentioned above) (10) and the coagulation cascade was recognised as an initiator of 
fibrosis, there is data showing it seems comprehensible that nearly no one uses 
anticoagulation for prevention of an exacerbation. Noth et al. showed that the use of 
vitamin K antagonist warfarin in IPF patients lead to a decline in survival.(42) This 
was also shown in patients who received oral anticoagulation, mainly vitamin K 
antagonists, for other medical reasons.(43)  
Most of the respondents identify the unmet needs of AE-IPF in the survey. Not only 
are treatment trials urgently needed but also trials addressing the pathophysiology of 
AE-IPF have to be expanded and an improved communication and collaboration 
between ILD specialists has to be supported.  
 
Our survey has several limitations. Although there was a significant contribution of 
pulmonologists from all parts of the world, it is based on a survey of physicians and 
not on objective evaluation of management and practices. Participation took place on 
voluntary basis and may not reflect the general practice in the respective 
countries/continents. While there was a significant contribution of pulmonologists 
from most parts of the world, there were only a few participants from Africa. Also it 
has to be mentioned certain variability in the approach of AE-IPF has to be 
associated with different local possibilities - between sites but also 
continents/countries. Especially, access to treatments such as immunomodulation 
like cyclophosphamide, cyclosporine or tacrolimus, antifibrotic drugs or ECMO might 
be limited in some countries.  
Furthermore, this study aimed to survey international habits on diagnosis and 
treatment of AE-IPF, it was unable to assess reliable information on incidences and 
outcomes of AE-IPF in the respective countries. This should be addressed in future 
work analysing current registries. 
Not all aspects of the management of AE-IPF could be addressed in the 
questionnaire. Our report also has strengths as we managed to get responses from 
all continents and from a significant number of physicians. The questionnaire was 
anonymous and therefore answers are anticipated to be less biased. 
 
In conclusion, the heterogeneity of management of AE-IPF as found in this 
international survey reflects the lack of evidence and focused guidelines on important 
aspects of the management of AE-IPF. This strongly calls for research, education, 
and collaborations between ILD-specialist around the world to find new ways to 
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Figure 1a.: Participants (n=217 (42%) from Europe, n=136 (27%) from Asia, n=57 (11%) from North America,  
















Figure 2. Main diagnostic procedures, statistically significant differences between continents are labeled 





















Figure 4. Preventive strategies, statistically significant differences between the continents are labeled 
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Thank you very much for accepting our invitation for this international survey on the diagnosis and
treatment of acute exacerbations of IPF -  a constant challenge in the treatment of patients with IPF.
We believe that your feedback will help all of us to establish future, international projects in order
to improve the diagnosis and treatment of this detrimental complication.
On behalf of the AE-IPF team within “The IPFProject”  
Kind regards,
Michael Kreuter
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Introductory questions to the participants:
Where are you from?
If you want to remain anonymous proceed to the next question.
Where is your working place?
Specialised ILD center / university center
Pneumology department (non-university center)
Intensive care unit 
Other 
How many IPF patients do you have in your practice or center?
0 400 800




What is your name? 
(and E-mail: voluntary, in case you want to be contacted for further projects of the "IPFproject")
If you want to remain anonymous proceed to the next question.
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire








Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Who do most patients with AE-IPF initially contact?
General practitioner (GP)
Another specialist (e.g. internal medicine, rheumatology)
A non-ILD specialized pulmonologist
A community clinic without specialized ILD center (including
emergency department)
A specialized ILD center
Other options
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Where should patients with an AE-IPF be hospitalized ideally if hospitalization is considered necessary?
A unit of interstitial lung diseases with possibility to be
transferred to an intensive care unit (ICU)
A unit of interstitial lung diseases without access to an ICU
A general pulmonology department / section with possibility
to be transferred to ICU
A general pulmonology department / section without an ICU
A department of internal medicine with possibility to be
transferred to ICU
A department of internal medicine without an ICU
 Other options
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Which laboratory tests are in your opinion / experience mandatory to be performed during diagnostic
workup of an AE-IPF? Multiple answers possible
Blood gas analysis
Standard laboratory values including CRP






Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Which further diagnostic procedures are in your opinion / experience mandatory to be performed during
diagnostic workup of an AE-IPF? Multiple answers possible
Chest x-ray
HRCT / multislice thin-section CT (without contrast media)
CT with contrast media (even in the absence of clinical
suspicion of pulmonary embolism)
Bronchoalveolar lavage always
Bronchoalveolar lavage only if infection is suspected and the




Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire







None of the above
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire





Screening for atypical pathogens (Serum and or urine)




None of the above
Others (e.g. other viruses):
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Do you treat AE-IPF with immunomodulation / corticosteroids? Multiple answers possible
Prednisolone 1 mg / kg / day, followed by slow tapering (over
weeks)
Methylprednisolone or equivalent 500 mg-1000 mg / day for 3
days, followed by slow tapering
Methylprednisolone or equivalent 500 mg-1000 mg / day






I never treat AE-IPF with any immunosuppressive therapy
Other immunosuppressive therapies:
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
You treat AE-IPF with other prednisolone dosages. 
Please, let us know the dosage:
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
You treat AE-IPF with corticosteroids. How long would you treat with steroids in weeks?
0 100
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
How would you rank your selected therapies?
(1=the therapy which is used most of time; if you have selected only one answer, please label it as 1)
Prednisolone 1 mg / kg / day, followed by slow tapering (over weeks)
Methylprednisolone or equivalent 500 mg-1000 mg / day for 3 days, followed by slow tapering






I never treat AE-IPF with any immunosuppressive therapy
[Insert text from Other]
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Do you use other therapies for AE-IPF? Multiple answers possible
Polymyxin B Hemoperfusion (or similar)
Recombinant Thrombomodulin
Plasmapheresis / plasma exchange
None of the above
Other therapeutical options:
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Which antimicrobial therapy do you commence regularly in AE-IPF? Multiple answers possible
Broad-spectrum antibiotics
Broad-spectrum antibiotics combined with macrolides
Antibiotic treatment only when there is a clinical and/or
laboratory indication for a bacterial infection




I do not agree with any of the answers
Other:
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
You use a broad spectrum antibiotic in AE-IPF.
Which broad spectrum antibiotic is your preferred choice?
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
A patient with pre-diagnosed IPF presents to you with AE-IPF without any previous antifibrotic treatment
and eligible for such a therapy.  What would be your choice as antifibrotic treatment ?
I would preferentially initiate Nintedanib
I would preferentially initiate Pirfenidone
I would initiate either antifibrotic without preference
I do not see an indication for antifibrotic therapy at all in this situation
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
You chose to initiate a therapy with Nintedanib in the patient with AE-IPF. When would you start the
treatment? 
Immediately
Only after stabilization of the patient
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
You chose to initiate a therapy with Pirfenidone in the patient with AE-IPF. When would you start the
treatment?
Immediately
Only after stabilization of the patient
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
You chose to initiate a therapy with either antifibrotic without preference in the patient with AE-IPF. When
would you start the treatment?
I would initiate ...
Immediately
Only after stabilization of the patient
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
A patient on treatment with Pirfenidone/Nintedanib (who tolerated the drug sufficiently) presents to you with
AE-IPF. What would you do?
Pirfenidone/Nintedanib should be continued unchanged
Treatment with any antifibrotic drug should be discontinued
Pirfenidone/Nintedanib should be continued at a reduced
dose
Treatment with the current antifibrotic drug should be stopped
and the alternative antifibrotic should be initiated if possible
Only in case of pretreatment with pirfenidone, this drug should
be discontinued and nintedanib initiated. In case of nintedanib
pretreatment I would continue with nintedanib due to the
reported effects on time to first acute exacerbation
Only in case of pretreatment with nintedanib, this drug should
be discontinued and pirfenidone initiated. In case of
pirfenidone pretreatment I would continue pirfenidone due to
the reported effects on respiratory hospitalizations.
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Please name PH drug(s) here (if answer 3 or 4 was chosen)
If you detect signs of pulmonary hypertension (PH) on clinical investigations (e.g. echo, BNP, clinical signs)
during an AE-IPF, how would you proceed? Multiple answers possible
Start diuretic therapy
Perform a right heart catheterization
Start PH specific treatment after established PH diagnosis
Start PH specific treatment without a confident diagnosis
Evaluate again after stabilization and possibly perform a right
heart catheterization then
I do not consider PH treatment during or after AE-IPF
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Would you initiate or increase the dose of an antacid drug (PPI / H2 blocker) when a patient presents with
an AE-IPF?
Always initiate or increase antacid drug therapy
Always make sure the patient receives antacid therapy but not increase the dose
Depending on the presence / intensity of reflux symptoms
Never prescribe antacid drug for this situation
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
What kind of ventilatory support would you offer critically ill patients with AE-IPF? Multiple answers
possible
Invasive Ventilation for all IPF patients
Invasive ventilation only to patients suitable for lung
transplantation (LTX) as a bridge to LTX
Invasive ventilation only to patients suitable for lung
transplantation (LTX) as a bridge to LTX or very selected
other patients
ECMO for all IPF patients
ECMO only to patients suitable for LTX as a bridge to LTX




None of the above
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Once AE-IPF is diagnosed, how would you talk to your patient and his caregivers?
I give them all information including treatment options and average prognosis during / after AE-IPF
I tell them an impression about treatment and prognosis but without telling hard facts
I prefer not to tell them anything on the fatal prognosis of an AE-IPF and only some impression on treatments
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Do you consider palliative care during an AE-IPF?
Always/Usually




Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
What is your general approach after hospitalization for AE-IPF? Multiple options possible
Send patients to pulmonary rehabilitation (in- or outpatient)
Reschedule patient shortly for a follow up at my center
If not contacted earlier during course of AE-IPF send eligible
patients for lung transplant evaluation
Refer patients not suitable for lung transplant to in- or
outpatient palliative or hospice care
Send patient home to be seen by their GP shortly for a follow
up
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire





Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
What is your strategy in the case of a planned surgical procedure in patients with IPF with respect to the
risk of acute exacerbations? Multiple answers possible
Surgical procedures can be performed in the same way in IPF
patients as in patients without IPF
Elective thoracic surgery for any reason should not be
performed
If surgery is necessary, use of low tidal volume and avoidance
of hyper-oxygenation to try to prevent injury
Preferentially use regional anesthesia (over general) when
possible
Elective thoracic surgery should only be performed in suitable
patients for the diagnosis of an ILD but not for other
indications (e.g. lung cancer)
Elective thoracic surgery should only be performed in suitable
patients for the diagnosis of an ILD or for lung cancer but not
for other indications
Any elective surgical procedures should be avoided and only
be performed in case of an emergency
I do not agree with any of the statements
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
What measures do you use to try to prevent AE-IPF? Multiple answers possible
Antifibrotic therapy
Vaccination (influenza, pneumococcal, etc.)
Antacids medication (PPI, H2 blockers) in all IPF patients
Low dose steroids (<10mg) in all IPF patients
Anticoagulants in all IPF patients
Azithromycine long term / maintenance
Cotrimoxazole long term / maintenance
Early screening for PH and treatment with PAH-drugs if PH is
diagnosed
Pulmonary rehabilitation or other forms of structured exercise
therapy
I do not have a preventive strategy
Others: 
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Where do you see the need for improvement in AE-IPF? Multiple answers possible
Improved collaboration between different ILD specialists in
general
Improved education and training of physicians
Improved education of patients and caregivers
Increased research and study projects on understanding the
nature of AE-IPF
Increased research and study projects on treatment of AE-IPF
Improved multidisciplinary strategies for diagnosing and
discussions
Consensus recommendations concerning the therapy for AE-
IPF
I do not see any need for improvements
Acute Exacerbations of Idiopathic Pulmonary Fibrosis - Questionnaire
Table 1: Diagnostic procedures of AE-IPF 
 




America  Oceania  Africa  p-value 
HRCT / multislice thin-section CT 
















CT with contrast media (even in the 











































































































Bronchoalveolar lavage only if 
infection is suspected and the 
patient is in an appropriate 












































































































Table 2: Treatments of AE-IPF 
 




America  Oceania  Africa  
p-
value 
Prednisolone 1 mg / kg / day, followed by 
















Methylprednisolone or equivalent 500 mg-
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Antibiotic treatment only when there is a 


































I do not see an indication for antifibrotic 




































Table 3: intensive and palliative care during AE-IPF 
 




America  Oceania  Africa  p-value 

















Invasive ventilation only to patients 
suitable for lung transplantation 
(LTX) as a bridge to LTX or very 
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Table 4: Prevention of AE-IPF 
 




America  Oceania  Africa  
p-
value 
If surgery is necessary, use of low 
tidal volume and avoidance of hyper-


































Any elective surgical procedures 
















































Antacids medication (PPI, H2 


































































Pulmonary rehabilitation or other 
forms of structured exercise therapy 
58% 
(N=427) 
61% 
(N=189) 
51% 
(N=118) 
57% 
(N=53) 
59% 
(N=41) 
67% 
(N=21) 
60% 
(N=5) 
0.582 
 
